Zydus Lifesciences: A Quarter of Robust Growth and Strategic Expansion in Q3 FY26

Zydus Lifesciences Limited has reported a strong performance for the third quarter of fiscal year 2026, showcasing significant growth across its key business segments. The innovation-led life sciences company, with a global footprint, announced consolidated revenues of ₹6,864.5 crore for Q3 FY26, marking a substantial 30% increase year-on-year. This impressive top-line growth was complemented by a healthy 31% rise in EBITDA, reaching ₹1,816.4 crore, with EBITDA margins improving by 20 basis points to 26.5%. While the adjusted net profit grew at a more modest 9% to ₹1,110.9 crore, the overall results underscore the company's sustained momentum and effective strategic execution.

The pharmaceutical business, which constitutes 81% of the consolidated revenues, was a primary driver of this growth. India Formulations led the charge, outperforming the market with a 14% year-on-year growth, fueled by innovative products and strong pillar brands. The chronic segment continued its accelerated growth trajectory, contributing significantly to the overall performance. North America Formulations also delivered a strong 16.4% YoY growth, driven by persistent volume expansion and new product launches in the US generics market. The International Markets (IM) Formulations segment demonstrated exceptional vitality, accelerating its growth trajectory with a 38.2% YoY increase, reflecting broad-based demand and focused execution across emerging markets and Europe. The company's API business also saw a healthy 25.8% YoY growth.

Diversified Growth Engines and Strategic Initiatives

Beyond its core pharmaceutical segments, Zydus Lifesciences showcased robust performance in its newer verticals. The Consumer Wellness business experienced a remarkable 113.4% YoY growth, with revenues reaching ₹957.8 crore. This surge was primarily attributed to the full quarter consolidation of the Comfort Click Limited (CCL) business, which continued to perform in line with expectations. Excluding CCL, the business still delivered double-digit volume growth, indicating strong underlying demand. The expansion of the Comfort Click portfolio with new adult gummy variants, probiotic gummies for kids, and Pure Himalayan Shilajit Resin further strengthens its position in high-growth wellness categories. The WeightWorld brand also expanded its European footprint, entering Poland, Finland, and Portugal.

The MedTech business, though smaller, also demonstrated significant growth, registering revenues of ₹299.6 crore, a substantial increase from the previous year, marking the first full quarter of consolidation for Amplitude Surgical's business. This diversification into consumer wellness and MedTech aligns with the company's strategy to